Clinical effect of improved VTD regimen combined with low-dose thalidomide in the treatment of multiple myeloma
10.3760/cma.j.issn.1008-6315.2015.09.016
- VernacularTitle:改良VTD方案联合低剂量沙利度胺治疗多发性骨髓瘤的效果观察
- Author:
Guihua ZHU
;
Xiumei LI
;
Wanchuan ZHUANG
;
Yajun JIANG
;
Yao HE
;
Xingxing CHAI
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Pirarubicin;
Vincristine;
Thalidomide;
Dexamethasone
- From:
Clinical Medicine of China
2015;31(9):823-825
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and adverse reactions of improved VTD regimen (pirarubicin combined with vincristine and dexamethasone) plus low-dose thalidomide in patients of newly diagnosed multiple myeloma(MM).Methods Twenty-nine cases of newly diagnosed MM were enrolled in this study.The improved VTD regimen was intravenous injection vincristine 2 mg/d on the first day,intravenous drip pirarubicin 20-30 mg/d from the first day to the second day,and intravenous drip dexamethasone 8 mg/d from the first day to the tenth day.Twenty-eight days was one course of treatment.Response and adverse reactions were evaluated after 4 course of treatment.On the first day of chemotherapy,all the patients were orally administered thalidomide 50 mg/d.Three days later,thalidomide was added to 100 mg/d and chronically maintained if toxicities could be tolerated.Results There were 3 cases(10.3％) in complete response,12 cases (41.2％) in very good partial response,10 cases (34.5％) in partial response,3 cases (10.3％) in stable disease,and 1 case(3.5％) in progressive disease.The overall response rate was 86.2％.Main adverse reactions were myelosuppression,asthenia and constipation,all could be tolerated.Conclusion It has significant response rate and less side effects of improved VTD regimen plus low-dose thalidomide for the patients of newly diagnosed multiple myeloma,and deserves further clinical practice.
